'India's Top-Selling Insulin Isn't Going Away, 10% Users To Be Impacted': Novo Nordisk India MD
Last Updated:
Vikrant Shrotriya said Human Mixtard is not being discontinued in India and will be supplied in vial presentation
In a big relief for Indian patients, Denmark-based Novo Nordisk said it is not discontinuing India's largest-selling insulin brand, Human Mixtard.
In recent weeks, concerns had been growing among diabetes patients over reports of a possible discontinuation of Human Mixtard. However, the largest-selling insulin brand will remain available in vials and not pens.
In an interview, Vikrant Shrotriya, Managing Director, Novo Nordisk India, told News18, 'Novo Nordisk India confirms that it is not discontinuing Human Mixtard in India and will continue to supply it in vial presentation along with other human insulins, including Human Actrapid and Human Insulatard."
The company's decision aligns with its global strategy. Globally, the Danish drug-maker is gradually winding up production of human insulin pens as it focuses on ramping up manufacturing of its latest and popular obesity or diabetes injections, including the blockbuster drug, Ozempic.
'In India, we will be phasing out human insulin in Penfill and FlexPen gradually by the end of this year. However, we continue to remain a very strong player with the largest insulin formulation offerings in India in all three generations, including human insulin, modern insulin and new generation insulin."
Shrotriya explained that as part of the global portfolio consolidation, Novo Nordisk has decided to phase out certain insulin products or devices, 'which reflects our ongoing efforts to continually improve our existing product offerings and to ensure that maximum patients have access to the most effective and innovative treatments available, globally".
'This will create space needed in our global manufacturing network, rationalise and make it sustainable in the long run to bring efficiency in Novo Nordisk product offerings."
Despite the price control, according to Pharmarack data, Mixtard was the eleventh most-selling brand in India in April, with its moving annual turnover (MAT) standing at Rs 766 crore. The second-largest insulin brand also comes from Novo Nordisk's portfolio, Ryzodeg, with a MAT of Rs 593 crore, followed by Sanofi's Lantus.
Why is human insulin no longer a priority?
In high-income countries or even in India, for those who can afford it, most people with diabetes now rely on modern insulin, as this kind of product offers more precise blood sugar control and greater flexibility in dosing.
However, in low- and middle-income countries or for people who want cheaper options, human insulin remains the more widely used option. It's significantly cheaper and easier to produce. However, it doesn't always provide the same level of control or convenience which can be achieved by the latest insulin options.
Who will be impacted & what are the options?
The company believes that 'of the overall patients on insulin in India, only 10 per cent are impacted," with this decision to phase out penfill and flexpen versions.
'They will have the choice of transitioning to modern and new generation insulin or continue human insulin through vials or other treatment options available in the market, based on the recommendation from their physician," Shrotriya said, adding that 'the remaining 90 per cent of patients using insulin remain unimpacted".
'We continue our unwavering commitment towards people with diabetes by continuing to serve every 'one in two' patients in India who require insulin," he said. 'Accordingly, we are doing everything we can to liaise early with health authorities, support healthcare professionals, trade partners and patients in the transition to other treatment options."
Currently, Novo Nordisk claims that it is the only company in India offering three generations of insulins to patients living with diabetes.
Will continue to invest in R&D
On being asked if this withdrawal will affect their overall insulin portfolio and research and development plans in India, Shrotriya explained that 'Novo Nordisk India contributes around 10 per cent to more than 40 global trials across therapy areas".
'We continue to invest in R&D to bring more innovations for the benefit of people living with serious chronic diseases, including improved insulins such as glucose-sensitive insulin, beta-cell replacement therapies and once-weekly insulin therapy."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
32 minutes ago
- Time of India
S Jaishankar welcomes Belgium's support and solidarity in combatting terrorism
BRUSSELS: External affairs minister began his visit to Belgium on Monday with a meeting with deputy prime minister and foreign minister Maxime Prevot. The discussions focused on enhancing bilateral cooperation and combating terrorism. Tired of too many ads? go ad free now He appreciated Belgium's support in combating terrorism and welcomed their solidarity and emphasised the strong momentum in the India-EU partnership, highlighting the potential for collaboration in clean energy, mobility, and pharmaceuticals. The two leaders discussed deepening cooperation in areas such as trade, investment, technology, defense, and security. Sharing the details in a post on X on Monday, EAM said, "Pleased to meet DPM & FM @prevotmaxime at the start of my visit to Belgium. Welcomed Belgium's support and solidarity in combatting terrorism. Appreciated the strong momentum of our bilateral engagement and the India - EU partnership. Also held wide - ranging discussions on deepening our cooperation including in trade, investment, technology, defence & security, pharmaceuticals, clean energy and mobility. " Jaishankar's visit to Brussels comes three months after Princess Astrid of Belgium led a 300-member economic mission to India. The recent visit by Princess Astrid, who met with Prime Minister Narendra Modi and Jaishankar, discussed key areas such as labor migration, pharmaceuticals, defense, diamonds, space exploration, and green energy. Interestingly, Jaishankar's visit coincides with the detention of fugitive Indian diamantaire Mehul Choksi in a Belgian jail. Choksi, accused of defrauding Punjab National Bank of Rs 13,850 crore, was arrested in mid-April on India's extradition request. Tired of too many ads? go ad free now India has an extradition treaty with Belgium, and the government is likely to pursue Choksi's extradition during the EAM's visit. Jaishankar is on an official visit to France, the European Union (EU), and Belgium from June 8 to 14, 2025, the Ministry of External Affairs announced in a press release on Sunday. The visit marks a significant step in further strengthening India's strategic partnerships with Europe. The EAM will first travel to Paris and Marseille, France, where he will hold bilateral discussions with the Minister for Europe and Foreign Affairs of France, Jean Noel Barrot. The EAM will hold a Strategic Dialogue with the EU High Representative and Vice President Kaja Kallas. According to the MEA press release, "India-European Union strategic partnership has strengthened over the years across diverse sectors and got a big boost with the first-ever visit of the EU College of Commissioners to India in February this year." Jaishankar will also meet senior leadership from the European Commission and European Parliament and interact with think tanks and media. MEA in its statement noted that the Belgium leg would also see the EAM meet members of the Indian community during his visit. The MEA highlighted, "India and Belgium share warm and friendly relations along with a very robust economic partnership. Today the collaboration between the two countries spans various domains like trade and investment, green energy, technology, pharmaceutical, diamond sector and strong people-to-people ties." The Ministry of External Affairs emphasized that the visit is expected to further deepen India's friendly relations with the European Union, France and Belgium and give renewed momentum to ongoing cooperation in diverse areas.
Time of India
37 minutes ago
- Time of India
Overnight lenses that reshape cornea could slow down myopia progression
Chennai: A new type of contact lens that can be worn overnight to help reshape the cornea and slow the eye's elongation, allowing people with myopia, or near-sightedness, to see without glasses or lenses during the day, will be tested in 200 children at city-based Dr Agarwals Eye Hospital for at least one and a half years, along with scientists from Japan. Myopia is a growing epidemic, afflicting the eyes of children, said the hospital's Chief Clinical Officer, Dr Ashvin Agarwal. People with myopia can see close-up objects clearly, but to read blackboards, engage in cycling, driving, or recognising the faces of people down the road, they may need glasses. "From a prevalence of 4% in 1999 to 21% in 2019, myopia is expected to affect 40% of India's population by 2040 and touch close to 50% by 2050. We are trying to slow down the progression," he said. Similarly, digital eye strain now affects 50%-60% of children in India, driven by increased screen time. Orthokeratology lenses are gas-permeable, rigid contact lenses that temporarily reshape the cornea of your eye. "People wear these lenses while they are sleeping. When they wake up and remove these lenses, their cornea holds its new shape, allowing them to see clearly without the need for glasses or daytime contact lenses," he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Pinga-Pinga e HBP? Tome isso 1x ao dia se tem mais de 40 anos Portal Saúde do Homem Clique aqui Undo In refractive errors, the cornea's shape is irregular, causing blurry vision. These lenses exert gentle hydraulic pressure on the tear film beneath the lens, which in turn reshapes the corneal cells, say experts. This temporary change in corneal curvature allows light to focus properly on the retina. Experts say they work like dental retainers that maintain the shape of teeth. "It must be worn every night. Our test will show who is benefiting from these glasses," he said. For the study, launched in Feb, Dr Agarwals Eye Hospital has collaborated with Japan's Menicon Co Ltd for joint research on these lenses. This study will check the efficacy and safety of the orthokeratology lens for Indian children. "We aim to develop solutions and raise awareness about the treatment," said Menicon Co Ltd regional director (China and Asia-Oceania) Shunsuke Yamagishi. These lenses won't be available for sale until doctors evaluate the benefits and side effects. "If this is successful, it will offer freedom from glasses and eventually show us the path towards a cure for myopia," Dr Agarwal said.
Time of India
an hour ago
- Time of India
India's trade agreement with EFTA to boost investments by $100 billion
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Bern, Switzerland: India's trade agreement with the European Free Trade Association (EFTA) comprising Switzerland, Norway, Iceland and Liechtenstein will come into effect in September, commerce and industry minister Piyush Goyal said on also said talks on a trade deal with the European Union could be concluded 'faster than expected'.India had already created a dedicated desk under Invest India for companies from the EFTA bloc to facilitate investment in India, he said, adding: "It will enter into force by September."The agreement has received approval from the parliaments of all four countries, Goyal said. In Switzerland, there is an objection period open until July 10 when citizens could challenge the pact. July and August are holiday months Delhi and the EFTA nations had signed the Trade and Economic Partnership Agreement (TEPA) on March 10, agreement envisages an investment commitment of $100 billion in 15 years from the grouping into India in lieu of customs duty cuts. This commitment, Goyal said, was included for the first time in a trade who is on a four-day visit to Switzerland and Sweden, said companies in biotech, cybersecurity, healthcare and machinery manufacturing have shown interest in investing in India. A delegation of 90 Indian companies is accompanying Goyal on this visit to meet local leaders and businesses to promote trade and said he held bilateral meetings with over a dozen companies here and most of them are keen to invest in India. He said a delegation of 100 companies had visited India in February and some of them are keen to test market their products"There is a lot of excitement here for India," he said, adding that the trade deal will bring predictability, continuity and stability of the policy regime for investors from both was talking to journalists after his meeting with Swiss industry Minister Narendra Modi's government, which has completed 11 years, has gone from a position of strength to negotiate free trade deals with advanced economies, Goyal Delhi is in talks with the US for a bilateral trade deal, he said. India has already signed an early harvest deal with Australia and is also actively negotiating agreements with New Zealand, Chile, Peru and trade dealAsked about if India is prepared to finalise a trade agreement with the US by prioritising low-hanging fruits, Goyal said: "India is always ready for that and I believe that" the things, which are not controversial, the low-hanging fruits, should be captured first as those sectors will start getting is not necessary to wait for everything and why waste time until it is perfect, he said, citing the example of trade officials are in New Delhi for the trade talks with their Indian counterparts. The week-long deliberations will conclude on June whether the deal can be concluded before July 9, he said: "I am a born optimist".During his meeting with companies here, Goyal suggested they organise board meetings in India so that they can see the investment potential in the country."The world today recognises that the best place to do business is India … India is also a preferred destination for services," he years of governmentTalking about the 11 years of the Modi government, Goyal said close to 2,000 GCC (global capability centres) had been set up in the are all possible because of "good governance" of the last 11 years, he said, while highlighting the reduction in extreme poverty and performance of stock markets. He also cited the gap between the yields on Indian bonds and the US treasury, which has narrowed from 6.3% in 2014 to 1.78% now.'PM Modi had taken the country from being a fragile five to being among the top five economies,' he saidGoyal said the government is trying to create large domestic accountancy firms in India, and the country will soon have its own "Big Four".Global professional services firms Deloitte, PricewaterhouseCoopers, EY and KPMG currently dominate the accountancy space in the country.
